{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(4)"],"submitter":["Rohrbacher L"],"pubmed_abstract":["<h4>Abstract</h4>T-cell-based immunotherapies have revolutionized treatment paradigms in B-cell malignancies, yet their translation to acute myeloid leukemia (AML) has been hindered by a scarcity of tumor-restricted antigens and the risk of on-target off-leukemia toxicity. FLT3 has emerged as a promising therapeutic target with limited expression in healthy hematopoietic tissues. Here, we performed a head-to-head preclinical comparison of an FMS-like tyrosine kinase 3 (FLT3)-directed bispecific T-cell engager (BiTE) molecule and second-generation FLT3-specific chimeric antigen receptor (CAR) T cells. Both approaches induced potent cytotoxicity against AML cell lines and primary patient-derived cells but spared healthy hematopoietic stem and progenitor cells in vitro. Despite similar short-"],"journal":["Blood advances"],"pagination":["1179-1193"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12917520"],"repository":["biostudies-literature"],"pubmed_title":["FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion."],"pmcid":["PMC12917520"],"pubmed_authors":["Hoffmann GV","Goldstein RL","Stadler H","Hanel G","Theurich S","Kobold S","Subklewe M","Brauchle B","Rohrbacher L","Kirmaier ME","Philipp N","Arvedson T","Marcinek A","Kazerani M","Gottschlich A","Richter D","Nixdorf D","Markl F","Straub T","Magno G","Bucklein V"],"additional_accession":[]},"is_claimable":false,"name":"FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.","description":"<h4>Abstract</h4>T-cell-based immunotherapies have revolutionized treatment paradigms in B-cell malignancies, yet their translation to acute myeloid leukemia (AML) has been hindered by a scarcity of tumor-restricted antigens and the risk of on-target off-leukemia toxicity. FLT3 has emerged as a promising therapeutic target with limited expression in healthy hematopoietic tissues. Here, we performed a head-to-head preclinical comparison of an FMS-like tyrosine kinase 3 (FLT3)-directed bispecific T-cell engager (BiTE) molecule and second-generation FLT3-specific chimeric antigen receptor (CAR) T cells. Both approaches induced potent cytotoxicity against AML cell lines and primary patient-derived cells but spared healthy hematopoietic stem and progenitor cells in vitro. Despite similar short-","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T09:57:53.858Z","creation":"2026-07-09T10:49:41.373Z"},"accession":"S-EPMC12917520","cross_references":{"pubmed":["41324594"],"doi":["10.1182/bloodadvances.2025018168"]}}